Profile
Sector:
HealthcareCountry:
United StatesIPO:
02 May 2014Website:
http://www.scynexis.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
SCYX Latest News
Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization and clinical development was paused due to manufacturing concerns, resulting in a 50% dip in SCYX valuation. However, the issue is expected to be resolved within few months. Considering cash runway >2 years, SCYX is sufficiently funded to resolve the issue and start having an income from milestones/royalties.
We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a single-product biotech, we see further downside to the stock price. Concerns around the impact on clinical trials, partnership with GSK, and uncertainty surrounding hospital-based fungal infection trials remain a key focus/risk moving forward.
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C.
Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.51 per share a year ago.
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone payments and royalties. SCYNEXIS retains rights to other assets derived from Brexafemme.
Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an antifungal for the treatment of vulvovaginal candidiasis and the reduction of the incidence of recurrent VVC.
What type of business is SCYNEXIS?
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
What sector is SCYNEXIS in?
SCYNEXIS is in the Healthcare sector
What industry is SCYNEXIS in?
SCYNEXIS is in the Drug Manufacturers - Specialty & Generic industry
What country is SCYNEXIS from?
SCYNEXIS is headquartered in United States
When did SCYNEXIS go public?
SCYNEXIS initial public offering (IPO) was on 02 May 2014
What is SCYNEXIS website?
https://www.scynexis.com
Is SCYNEXIS in the S&P 500?
No, SCYNEXIS is not included in the S&P 500 index
Is SCYNEXIS in the NASDAQ 100?
No, SCYNEXIS is not included in the NASDAQ 100 index
Is SCYNEXIS in the Dow Jones?
No, SCYNEXIS is not included in the Dow Jones index
When does SCYNEXIS report earnings?
The next expected earnings date for SCYNEXIS is 14 August 2024